IP Library Granted Patent US 8,163,790
Granted Patent B2
US 8,163,790 · App. 12/096,998 · Granted Apr 24, 2012

Metronidazole cocrystals and imipramine cocrystals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,790
App. No.
12/096,998
Granted
Apr 24, 2012
Kind
B2
Abstract

Cocrystals of metronidazole are described herein. Such cocrystals are a cocrystal of metronidazole with gentisic acid and a cocrystal of metronidazole with gallic acid. Cocrystals of imipramine hydrochloride are also described. Such cocrystals are a cocrystal of imipramine hydrochloride with (+)-camphoric acid, a cocrystal of imipramine hydrochloride with fumaric acid, and a cocrystal of imipramine hydrochloride with 1-hydroxy-2-naphthoic acid.

Claims (15)

1. A cocrystal of metronidazole and gentisic acid having about a 1:1 molar ratio of metronidazole to gentisic acid in the unit cell and an x-ray diffracton peak at about 14.5 °2θ.

2. The cocrystal of metronidazole and gentisic acid of claim 1 having substantially the same x-ray diffraction pattern as FIG. 1 .

3. A cocrystal of metronidazole and gentisic acid having about a 1:1 molar ratio of metronidazole to gentisic acid in the unit cell and a Raman peak at about 1189.7 cm −1 .

4. The cocrystal metronidazole and gentisic acid of claim 3 having a Raman spectrum substantially the same as FIG. 5 .

5. A cocrystal of metronidazole and gallic acid having about a 1:1 molar ratio of metronidazole to gallic acid in the unit cell and an x-ray powder diffraction peak at about 15.2 °2θ.

6. The cocrystal of metronidazole and gallic acid of claim 5 having an x-ray powder diffraction pattern that is substantially the same as FIG. 6 .

7. A cocrystal of metronidazole and gallic acid having about a 1:1 molar ratio of metronidazole to gallic acid in the unit cell and a Raman peak at 1493.5 cm −1 .

8. The cocrystal of metronidazole and gallic acid of claim 7 having a Raman spectrum substantially the same as that of FIG. 8 .

9. A cocrystal of imipramine hydrochloride and (+)-camphoric acid having about a 1:1 molar ratio of imipramine hydrochloride to (+)-camphoric acid in the unit cell and an x-ray powder diffraction peak at about 5.4 °2θ.

10. The cocrystal of imipramine hydrochloride and (+)-camphoric add of claim 9 having substantially the same x-ray powder diffraction pattern of FIG. 9 .

11. A cocrystal of imipramine hydrochloride and (+)-camphoric add having about a 1:1 molar ratio of imipramine hydrochloride to (+)-camphoric acid in the unit cell and a Raman peak at about 1059.1 cm −1 .

12. The cocrystal of imipramine hydrochloride and (+)-camphoric acid of claim 11 having a Raman spectrum substantially the same as that of FIG. 15 .

13. A pharmaceutical composition comprising a 1:1 cocrystal of metronidazole and gentisic acid having an x-ray diffraction peak at about 14.5 °2θ and one or more pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a 1:1 cocrystal of metronidazole and gallic acid having an x-ray powder diffraction peak at about 15.2 °2θ and one or more pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a 1:1 cocrystal of imipramine hydrochloride and (+)-camphoric acid having an x-ray powder diffraction peak at about 5.4 °2θ and one or more pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2012
From: APTUIT (KANSAS CITY), LLC
To: NEW FORM PHARMACEUTICALS INC.
Reel/Frame 027835/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2008
From: CHILDS, SCOTT LAWRENCE
To: SSCI, INC.
Reel/Frame 022041/0713 →
MERGER Recorded Dec 20, 2008
From: SSCI, INC.
To: APTUIT (KANSAS CITY), LLC
Reel/Frame 022012/0049 →